Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes
Status:
Withdrawn
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
This study will test the hypothesis that oral repaglinide is equivalent to insulin in the
treatment of new-onset CFRD in adolescents. In addition, successful treatment of CFRD with
repaglinide will improve nutritional status, ameliorate declines in pulmonary function, and
will not have a negative impact upon quality of life.